Avenue Therapeutics Stock Forecast, Price & News

+0.15 (+2.24 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $6.86
50-Day Range
MA: $5.95
52-Week Range
Now: $6.86
Volume1.04 million shs
Average Volume216,841 shs
Market Capitalization$114.89 million
P/E RatioN/A
Dividend YieldN/A
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
Avenue Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ATXI
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$0.41 per share


Net Income$-25,910,000.00


Market Cap$114.89 million
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable


Appleton’s Avenue of Ice
February 20, 2021 |
See More Headlines


Overall MarketRank

0.77 out of 5 stars

Medical Sector

1209th out of 2,010 stocks

Pharmaceutical Preparations Industry

535th out of 769 stocks

Analyst Opinion: 1.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+0.15 (+2.24 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

Is Avenue Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Avenue Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATXI, but not buy additional shares or sell existing shares.
View analyst ratings for Avenue Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Avenue Therapeutics?

Wall Street analysts have given Avenue Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avenue Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Avenue Therapeutics

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its quarterly earnings data on Tuesday, March, 30th. The company reported ($0.06) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.06).
View Avenue Therapeutics' earnings history

How has Avenue Therapeutics' stock been impacted by Coronavirus?

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATXI shares have decreased by 7.8% and is now trading at $6.86.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ATXI?

1 analysts have issued 1 year price targets for Avenue Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Avenue Therapeutics' share price to reach $6.00 in the next year. This suggests that the stock has a possible downside of 12.5%.
View analysts' price targets for Avenue Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 66)
  • Dr. Xiaoqin Lu M.D., Pres, CEO & Director (Age 46, Pay $639.78k)
  • Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 37, Pay $258.78k)
  • Dr. Scott A. Reines, Interim Chief Medical Officer (Age 74)

Who are some of Avenue Therapeutics' key competitors?

What other stocks do shareholders of Avenue Therapeutics own?

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $6.86.

How much money does Avenue Therapeutics make?

Avenue Therapeutics has a market capitalization of $114.89 million. The company earns $-25,910,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Avenue Therapeutics have?

Avenue Therapeutics employs 4 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is

Where are Avenue Therapeutics' headquarters?

Avenue Therapeutics is headquartered at 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 4/10/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.